Established in the summer of 2002, the Center for Biotechnology and Genomic Medicine (CBGM) at the Georgia Regents University (GRU) was developed to promote interdisciplinary and translational research in Biotechnology and Genomic Medicine with the ultimate goal of promoting predictive, preventive, personalized and participatory (4P) medicine.
The Center's research efforts focus on two main areas: 1) discovery and validation of biomarkers for disease prediction and diagnosis, 2) pharmacomics and drug discovery for personalized medicine. CBGM is home of four internationally renowned programs in diabetes research: The Environmental Determinants of Diabetes in the Young (TEDDY), the Prospective Assessment in Newborns of Diabetes Autoimmunity (PANDA), the Diabetic Complications Consortium (DiaComp) and the Mouse Metabolic Phenotype Consortium (MMPC). Additional research programs include autoimmune diseases, transplantation, and cancer. These research programs are supported by an annual extramural funding of approximately $12 million.
The center houses several state-of-the-art high throughput and high content facilities for genetics, genomics, proteomics, drug screening and bioinformatics. The center continues to recruit independent investigators with expertise in diverse disciplines such as genomics, proteomics, immunology, medicinal chemistry, drug development, biostatistics and computational biology. This multidisciplinary approach provides an avenue for investigators to interact and stimulate novel ideas.